Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM PAR
-
Total 13F shares
-
67,441,197
-
Share change
-
+9,404,737
-
Total reported value
-
$27,977,000
-
Put/Call ratio
-
58%
-
Price per share
-
$0.41
-
Number of holders
-
39
-
Value change
-
+$3,982,206
-
Number of buys
-
17
-
Number of sells
-
13
Institutional Holders of SUNESIS PHARMACEUTICALS INC - COM PAR (SNSS) as of Q1 2020
As of 31 Mar 2020,
SUNESIS PHARMACEUTICALS INC - COM PAR (SNSS) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,441,197 shares.
The largest 10 holders included
Aisling Capital Management LP, Nantahala Capital Management, LLC, CAXTON CORP, BVF INC/IL, Samsara BioCapital, LLC, Avidity Partners Management LP, VANGUARD GROUP INC, CITADEL ADVISORS LLC, Corriente Advisors, LLC, and MPM ONCOLOGY IMPACT MANAGEMENT LP.
This page lists
39
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.